{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:21:46Z","timestamp":1787026906626,"version":"build-2736575974"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Brain metastases (BM) represent the most frequent intracranial tumors with increasing incidence. Many primary tumors are currently treated in protocols that incorporate targeted therapies either upfront or for progressive metastatic disease. Hence, molecular markers are gaining increasing importance in the diagnostic framework of BM. In cases with diagnostic uncertainty, both in newly diagnosed or recurrent BM, stereotactic biopsy serves as an alternative to microsurgical resection particularly whenever resection is not deemed to be safe or feasible. This retrospective study aimed to analyze both diagnostic yield and safety of an image-guided frame based stereotactic biopsy technique (STX).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>Our institutional neurosurgical data base was searched for any surgical procedure for suspected brain metastases between January 2016 and March 2021. Of these, only patients with STX were included. Clinical parameters, procedural complications, and tissue histology and concomitant molecular signature were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 467 patients were identified including 234 (50%) with STX. Median age at biopsy was 64 years (range 29 \u2013 87 years). MRI was used for frame-based trajectory planning in every case with additional PET-guidance in 38 cases (16%). In total, serial tumor probes provided a definite diagnosis in 230 procedures (98%). In 4 cases (1.7%), the pathological tissue did not allow a definitive neuropathological diagnosis. 24 cases had to be excluded due to non-metastatic histology, leaving 206 cases for further analyses. 114 patients (49%) exhibited newly diagnosed BM, while 46 patients (20%) displayed progressive BM. Pseudoprogression was seen in 46 patients, a median of 12 months after prior therapy. Pseudoprogression was always confirmed by clinical course. Metastatic tissue was found most frequently from lung cancer (40%), followed by breast cancer (9%), and malignant melanoma (7%). Other entities included gastrointestinal cancer, squamous cell cancer, renal cell carcinoma, and thyroid cancer, respectively. In 9 cases (4%), the tumor origin could not be identified (cancer of unknown primary). Molecular genetic analyses were successful in 137 out of 144 analyzed cases (95%). Additional next-generation sequencing revealed conclusive results in 12\/18 (67%) cases. Relevant peri-procedural complications were observed in 5 cases (2.4%), which were all transient. No permanent morbidity or mortality was noted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with BM, frame-based stereotactic biopsy constitutes a safe procedure with a high diagnostic yield. Importantly, this extended to discerning pseudoprogression from tumor relapse after prior therapy. Thus, comprehensive molecular characterization based on minimal-invasive stereotactic biopsies lays the foundation for precision medicine approaches in the treatment of primary and recurrent BM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2022.1014711","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T03:22:26Z","timestamp":1671506546000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine"],"prefix":"10.3389","volume":"12","author":[{"given":"Sophie","family":"Katzendobler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Rejeski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario M.","family":"Dorostkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie L.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Forbrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Niyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Egensperger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg-Christian","family":"Tonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"von Baumgarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Thon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab101","article-title":"Epidemiology of brain metastases and leptomeningeal disease","volume":"23","author":"Lamba","year":"2021","journal-title":"Neuro Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-811161-1.00002-5","article-title":"Brain metastases: epidemiology","volume":"149","author":"Ostrom","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2021.07.032","article-title":"The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy","volume":"156","author":"Karschnia","year":"2021","journal-title":"Eur J cancer."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002459","article-title":"Systematic review of combinations of targeted or immunotherapy in advanced solid tumors","volume":"9","author":"Tan","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-014-1350-7","article-title":"Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues","volume":"128","author":"Berghoff","year":"2014","journal-title":"Acta Neuropathol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discovery"},{"key":"B10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00058-2017","article-title":"Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients","volume":"4","author":"Cadranel","year":"2018","journal-title":"ERJ Open Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020593","article-title":"Treatment of brain metastases of non-small cell lung carcinoma","volume":"22","author":"Rybarczyk-Kasiuchnicz","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx702","article-title":"Overview of current systemic management of EGFR-mutant NSCLC","volume":"29","author":"Hsu","year":"2018","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2233","article-title":"The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial","volume":"20","author":"Costa","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-019-02189-8","article-title":"Tumor microenvironment differences between primary tumor and brain metastases","volume":"18","author":"Cacho-Diaz","year":"2020","journal-title":"J Transl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nec.2020.06.007","article-title":"Brain metastasis recurrence versus radiation necrosis: Evaluation and treatment","volume":"31","author":"Lee","year":"2020","journal-title":"Neurosurg Clin N Am"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000763","article-title":"Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma","volume":"5","author":"Le Rhun","year":"2020","journal-title":"ESMO Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/neuonc\/noz147","article-title":"Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression","volume":"22","author":"Galldiks","year":"2020","journal-title":"Neuro Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"100424","DOI":"10.1016\/j.esmoop.2022.100424","article-title":"MRI-Based contrast clearance analysis shows high differentiation accuracy between radiation-induced reactions and progressive disease after cranial radiotherapy","volume":"7","author":"Bodensohn","year":"2022","journal-title":"ESMO Open"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.822362","article-title":"Diagnostic yield and complication rate of stereotactic biopsies in precision medicine of gliomas","volume":"13","author":"Katzendobler","year":"2022","journal-title":"Front Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/1740774517698645","article-title":"Common terminology criteria for adverse events (CTCAE) version","volume":"5","year":"2017"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03765-z","article-title":"PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression","volume":"153","author":"Weller","year":"2021","journal-title":"J Neurooncol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.248278","article-title":"Treatment monitoring of immunotherapy and targeted therapy using (18)F-FET PET in patients with melanoma and lung cancer brain metastases: Initial experiences","volume":"62","author":"Galldiks","year":"2021","journal-title":"J Nucl Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz003","article-title":"PET imaging in patients with brain metastasis-report of the RANO\/PET group","volume":"21","author":"Galldiks","year":"2019","journal-title":"Neuro Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now241","article-title":"Diagnosis and treatment of brain metastases from solid tumors: Guidelines from the European association of neuro-oncology (EANO)","volume":"19","author":"Soffietti","year":"2017","journal-title":"Neuro Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1602697","article-title":"Efficacy, safety, and duration of a frameless fiducial-less brain biopsy versus frame-based stereotactic biopsy: A prospective randomized study","volume":"79","author":"Georgiopoulos","year":"2018","journal-title":"J Neurol Surg A Cent Eur Neurosurg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/02688690220131705","article-title":"The advantages of frameless stereotactic biopsy over frame-based biopsy","volume":"16","author":"Dorward","year":"2002","journal-title":"Br J Neurosurg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3171\/2009.3.JNS081695","article-title":"Comparing the risks of frameless stereotactic biopsy in eloquent and noneloquent regions of the brain: a retrospective review of 284 cases","volume":"111","author":"Air","year":"2009","journal-title":"J Neurosurg"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-021-03785-9","article-title":"Clinical outcomes as a function of the number of samples taken during stereotactic needle biopsies: a meta-analysis","volume":"154","author":"Dhawan","year":"2021","journal-title":"J Neurooncol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3171\/2014.10.JNS141610","article-title":"Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors","volume":"123","author":"Sneed","year":"2015","journal-title":"J Neurosurg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox090","article-title":"Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis","volume":"19","author":"Narloch","year":"2017","journal-title":"Neuro Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2217\/cns-2016-0038","article-title":"Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine","volume":"6","author":"Lazaro","year":"2017","journal-title":"CNS Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.885472","article-title":"Current treatment approaches and global consensus guidelines for brain metastases in melanoma","volume":"12","author":"Tan","year":"2022","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126477","article-title":"Brain metastases management in oncogene-addicted non-small cell lung cancer in the targeted therapies era","volume":"23","author":"De Carlo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2016-0170","article-title":"Sequencing brain metastases and opportunities for targeted therapies","volume":"18","author":"Chukwueke","year":"2017","journal-title":"Pharmacogenomics."},{"key":"B39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11912-018-0695-9","article-title":"Emerging trends in the management of brain metastases from non-small cell lung cancer","volume":"20","author":"Churilla","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-Small-Cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac118","article-title":"Brain metastases: A society for neuro-oncology (SNO) consensus review on current management and future directions","author":"Aizer","year":"2022","journal-title":"Neuro Oncol"},{"key":"B44","article-title":"Management of brain metastases in the era of targeted and immunomodulatory therapies","volume":"29","author":"Brastianos","year":"2015","journal-title":"Oncol (Williston Park)."},{"key":"B45","doi-asserted-by":"publisher","first-page":"R119","DOI":"10.1186\/bcr3244","article-title":"Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain","volume":"14","author":"Duchnowska","year":"2012","journal-title":"Breast Cancer Res BCR."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.01.003","article-title":"The evolving landscape of brain metastasis","volume":"4","author":"Valiente","year":"2018","journal-title":"Trends Cancer."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz012","article-title":"Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications","volume":"21","author":"Boire","year":"2019","journal-title":"Neuro Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"E67","DOI":"10.1093\/neuros\/nyaa334","article-title":"A liquid biopsy to assess brain tumor recurrence: Presence of circulating Mo-MDSC and CD14+ VNN2+ myeloid cells as biomarkers that distinguish brain metastasis from radiation necrosis following stereotactic radiosurgery","volume":"88","author":"Soler","year":"2020","journal-title":"Neurosurgery."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1014711\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T10:33:01Z","timestamp":1673951581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1014711\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":48,"alternative-id":["10.3389\/fonc.2022.1014711"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1014711","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"article-number":"1014711"}}